NCT06345001View on ClinicalTrials.gov

A First-in-Human Study to Learn About How BAY3630942 is Distributed and Processed Inside the Body When Given After BAY3547922 and How Safe it is in People With Liver Cancer or Other Select Solid Cancers

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

August 26, 2024

Primary Completion Date

March 10, 2025

Study Completion Date

March 31, 2025

Conditions
Hepatocellular Carcinoma (HCC)Solid Tumors
Interventions
DRUG

BAY3630942

IV, Single administration

DRUG

BAY3547922

IV, Single infusion

Trial Locations (4)

33165

Biogenix Molecular, LLC, Miami

85258

HonorHealth Research Institute, Scottsdale

91010

City of Hope - Duarte Cancer Center, Duarte

90089-1019

University of Southern California (USC) - Norris Comprehensive Cancer Center, Los Angeles

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT06345001 - A First-in-Human Study to Learn About How BAY3630942 is Distributed and Processed Inside the Body When Given After BAY3547922 and How Safe it is in People With Liver Cancer or Other Select Solid Cancers | Biotech Hunter | Biotech Hunter